<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961100</url>
  </required_header>
  <id_info>
    <org_study_id>GP41341</org_study_id>
    <secondary_id>2019-000783-15</secondary_id>
    <nct_id>NCT03961100</nct_id>
  </id_info>
  <brief_title>A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.</brief_title>
  <official_title>A Randomized, Open-Label, Two Part Study to Explore the Performance of Entrectinib Prototype Mini-Tablet Formulations and the Effect of Drug Substance Particle Size On Entrectinib Bioavailability in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the bioavailability, palatability, safety and tolerability of
      entrectinib in healthy volunteers. Part 1 of the study will explore the performance of
      entrectinib multi-particle formulation. Part 2 will evaluate the effect of drug substance
      particle size on entrectinib bioavailability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Actual">August 9, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve from Time 0 to infinity (AUC0-inf) of entrectinib</measure>
    <time_frame>From Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: AUC0-inf of entrectinib active metabolite M5</measure>
    <time_frame>From Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration (Cmax) of entrectinib</measure>
    <time_frame>From Day 1 to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax of M5</measure>
    <time_frame>From Day 1 to Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with adverse events</measure>
    <time_frame>From Day -1 to Day 5</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Palatability of uncoated multi-particle formulation of entrectinib assessed by palatability questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>The questionnaire will assess the acceptability and taste of entrectinib formulation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib 600 mg (T1)</intervention_name>
    <description>Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib 600 mg (T2)</intervention_name>
    <description>Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib 200 mg (R)</intervention_name>
    <description>Reference formulation (R): entrectinib hard capsules</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib 200 mg (T)</intervention_name>
    <description>Test formulation (T): entrectinib HPMC capsules</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (BMI) between 18.0 and 32.0 kilogram per square meter (kg/m2),
             inclusive, and weighing &gt;/=50 kg.

          -  Agreement to comply with measures to prevent pregnancy and restrictions on egg and
             sperm donation

        Exclusion Criteria:

          -  Women of childbearing potential, women who are pregnant or breastfeeding, or intending
             to become pregnant during the study or within 14 days after the final dose of
             entrectinib or have a pregnant partner

          -  A clinical significant medical history of gastrointestinal surgery (e.g., gastric
             bypass) or other gastrointestinal disorder (e.g., malabsorption syndrome) that might
             affect absorption of medicines from the gastrointestinal tract

          -  Presence of a clinically significant disease, illness, medical condition or disorder,
             or any other medical history determined by the investigator to be clinically
             significant and relevant

          -  Clinically significant change in health status, or any major illness, or clinically
             significant acute infection or febrile illness

          -  Use of moderate or potent inhibitors or inducers of CYP P450 3A4 enzyme or P-gp
             transporter, or use of other prohibited medications

          -  Participation in any other clinical study involving an investigational medicinal
             product (IMP) or device

          -  A positive test result for hepatitis B, hepatitis C (HCV), or human immunodeficiency
             virus (HIV)

          -  Current smokers and those who have smoked, or users of e-cigarettes and nicotine
             replacement products within the last 12 months

          -  Known history of clinically significant hypersensitivity, or severe allergic reaction,
             to entrectinib or related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical Ltd, Clinical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

